Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report
Hamid Mirshahidi , Sue Min Sophia Kwon , Alberto Romagnolo , Kiwon Park , Adam Hagele
{"title":"Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report","authors":"Hamid Mirshahidi , Sue Min Sophia Kwon , Alberto Romagnolo , Kiwon Park , Adam Hagele","doi":"10.1016/j.cpccr.2023.100246","DOIUrl":null,"url":null,"abstract":"<div><p>RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621923000303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
